Choosing an equivalence limit for noninferiority or equivalence studies

Rothman, 1994, The continuing unethical use of placebo controls, N Engl J Med, 331, 394, 10.1056/NEJM199408113310611

Temple, 1997, When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?, Control Clin Trials, 18, 613, 10.1016/S0197-2456(97)00058-5

Temple, 2000, Placebo-controlled trials and active-control trials in the evaluation of new treatments, Part 1, Ann Intern Med, 133, 455, 10.7326/0003-4819-133-6-200009190-00014

Ellenberg, 2000, Placebo-controlled trials and active-control trials in the evaluation of new treatments, Part 2, Ann Intern Med, 133, 464, 10.7326/0003-4819-133-6-200009190-00015

Simon, 2000, Are placebo-controlled clinical trials ethical or needed when alternative treatment exists?, Ann Intern Med, 133, 474, 10.7326/0003-4819-133-6-200009190-00017

Blackwelder, 1982, “Proving the null hypothesis” in clinical trials, Control Clin Trials, 3, 345, 10.1016/0197-2456(82)90024-1

Schuirmann, 1987, A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability, J Pharmacokinet Biopharm, 15, 657, 10.1007/BF01068419

Holmgren, 2000, Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained, J Biopharm Stat, 9, 651, 10.1081/BIP-100101201

Windeler, 1996, Recommendations concerning studies on therapeutic equivalence, Drug Inf J, 30, 195, 10.1177/009286159603000123

Temple, 1996, Problems in interpreting active control equivalence trials, Accountability in Research, 4, 267, 10.1080/08989629608573887

Jones, 1996, Trials to assess equivalence, BMJ, 313, 36, 10.1136/bmj.313.7048.36

Rosenkranz, 1997, Can we reduce the dose of a vaccine?, Control Clin Trials, 18, 43, 10.1016/S0197-2456(95)00261-8

Stenijans, 1998, Asthma management, Int J Clin Ther, 36, 117

Califf, 1998, A perspective on the regulation of the evaluation of antithrombotic drugs, Am J Cardiol, 82, 25P, 10.1016/S0002-9149(98)00661-4

Ebbutt, 1998, Practical issues in equivalence trials, Stat Med, 17, 1691, 10.1002/(SICI)1097-0258(19980815/30)17:15/16<1691::AID-SIM971>3.0.CO;2-J

Hauck, 1999, Some issues in the design and analysis of equivalence trials, Drug Inf J, 33, 109, 10.1177/009286159903300114

Hwang, 1999, Design issues in noninferiority/equivalence trials, Drug Inf J, 33, 1205, 10.1177/009286159903300424

Siegel, 2000, Equivalence and noninferiority trials, Am Heart J, 139, S166, 10.1016/S0002-8703(00)90066-8

Källén, 2000, On the definition of therapeutic equivalence, Drug Inf J, 34, 349, 10.1177/009286150003400203

Gould, 1993, Sample sizes for event rate equivalence trials using prior information, Stat Med, 12, 2009, 10.1002/sim.4780122105

Garbe, 1993, Clinical and statistical issues in therapeutic equivalence trials, Eur J Clin Pharmacol, 45, 1, 10.1007/BF00315342

International Conference on Harmonisation. E9: Guidance on statistical principles for clinical trials. Federal Register 63(179), September 16, 1998.

International Conference on Harmonisation. E10: Choice of control group in clinical trials. Federal Register 64(185), September 24, 1999.

Guidance for industry: clinical development programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. Food and Drug Administration, Washington, DC, February 1999.

Meyerson, 2000, Understanding clinical trials

Concept paper on the development of a committee for proprietary medicinal products (CPMP) points to consider on biostatistical/methodological issues arising from recent CPMP discussions on licensing applications: choice of delta. Committee on Proprietary Medicinal Products, London, 23 September 1999.

Hasselblad, 2001, Statistical methods for comparison to placebo in active-control trials, Drug Inf J, 35, 435, 10.1177/009286150103500212

Cook, 1995, The number needed to treat, BMJ, 310, 452, 10.1136/bmj.310.6977.452

Fleming, 2000, Design and interpretation of equivalence trials, Am Heart J, 139, S171, 10.1016/S0002-8703(00)90067-X

Giani, 1994, Testing and selecting for equivalence with respect to a control, J Am Stat Assoc, 89, 320, 10.2307/2291228

Feinstein, 1999, Indexes of contrast and quantitative significance for comparisons of two groups, Stat Med, 18, 2557, 10.1002/(SICI)1097-0258(19991015)18:19<2557::AID-SIM361>3.0.CO;2-R

Lenth, 2001, Some practical guidelines for effective sample size determination, The American Statistician, 55, 187, 10.1198/000313001317098149

Ponnapalli RM, Dubey SD. Nonparametric tests for equivalence. ASA 1991 Proceedings of the Biopharmaceutical Section. 1991. p. 102–105.

Hauck, 2000, Generalized treatment effects for clinical trials, Stat Med, 19, 887, 10.1002/(SICI)1097-0258(20000415)19:7<887::AID-SIM388>3.0.CO;2-L

Heyse JF, Stine R. Use of the overlapping coefficient for measuring the similarity of treatments. ASA 2000 Proceedings of the Biopharmaceutical Section. 2000, p. 29–32.

Points to consider: clinical development and labeling of anti-infective drug products. Food and Drug Administration Division of Anti Infective Drug Products, Washington, DC, October 26, 1992.

Bristol, 1996, Determining equivalence and the impact of sample size in anti-infective studies, J Biopharm Stat, 6, 319, 10.1080/10543409608835146

Wiens, 2001, Testing noninferiority of response rates for regulatory filings using transformations, Drug Inf J, 35, 1165, 10.1177/009286150103500413

Wiens, 1999, On testing equivalence of three populations, J Biopharm Stat, 9, 465, 10.1081/BIP-100101188

Wiens, 2000, Design and analysis of three treatment equivalence trials, Control Clin Trials, 21, 127, 10.1016/S0197-2456(99)00052-5

Ng T-H. Equivalence testing with three or more treatment groups. American Statistical Association 2000 Proceeding of the Biopharmaceutical Section. 2000, p. 156–160.

Wiens BL, Heyse JF, Matthews H. Similarity of three treatments, with application to vaccine development. ASA 1996 Proceedings of the Biopharmaceutical Section. 1996, p. 203–206.

Dunnett, 1996, An alternative to the use of two-sided tests in clinical trials, Stat Med, 15, 1729, 10.1002/(SICI)1097-0258(19960830)15:16<1729::AID-SIM334>3.0.CO;2-M

Morikawa, 1995, A useful testing strategy in phase III trials, J Biopharm Stat, 5, 297, 10.1080/10543409508835115

Chuang-Stein, 1999, Clinical equivalence—a clarification, Drug Inf J, 33, 1189, 10.1177/009286159903300422

Ng, 2001, Choice of delta in equivalence testing, Drug Inf J, 35, 1517, 10.1177/009286150103500446